secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clarus Therapeutics Holdings, Inc. (—)
CIK:        0001817944
Form:       8-K
Filed at:   2023-03-01T23:59:59+00:00
Accession:  0001213900-23-015846
Event type: other_material
Sentiment:  negative
Materiality: 1.00
Item codes: 1.03, 2.01, 3.03, 5.01, 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Clarus Therapeutics completes Chapter 11 liquidation; all common stock cancelled
--------------------------------------------------------------------------------

- Plan effective Feb 28, 2023; all outstanding common stock cancelled and discharged.
- Board of directors dissolved as of the Effective Date.
- Company intends to file Form 15 to deregister securities and suspend SEC reporting.
- Previously sold JATENZO assets to Tolmar in Oct 2022; sale approved by bankruptcy court.
- Clarus will cease periodic reporting obligations upon Form 15 filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/0001213900-23-015846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817944/000121390023015846/ea174454-8k_clarus.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-015846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer